MCE - Delayed Quote • EUR
Laboratorios Farmaceuticos Rovi, S.A. (ROVI.MC)
At close: April 26 at 5:35 PM GMT+2
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2022) | Next Qtr. (Mar 2023) | Current Year (2022) | Next Year (2023) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | 10 | 10 |
| Avg. Estimate | 0 | 0 | 3.24 | 2.71 |
| Low Estimate | 0 | 0 | 2.94 | 1.57 |
| High Estimate | 0 | 0 | 3.74 | 3.39 |
| Year Ago EPS | -- | -- | 2.76 | 3.24 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2022) | Next Qtr. (Mar 2023) | Current Year (2022) | Next Year (2023) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | 10 | 10 |
| Avg. Estimate | -- | -- | 778.69M | 735.62M |
| Low Estimate | -- | -- | 723M | 665M |
| High Estimate | -- | -- | 805M | 826M |
| Year Ago Sales | -- | -- | 648.68M | 778.69M |
| Sales Growth (year/est) | -- | -- | 20.00% | -5.50% |
Earnings History
| CURRENCY IN USD | ||||
|---|---|---|---|---|
| EPS Est. | -- | -- | -- | -- |
| EPS Actual | -- | -- | -- | -- |
| Difference | -- | -- | -- | -- |
| Surprise % | -- | -- | -- | -- |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Dec 2022) | Next Qtr. (Mar 2023) | Current Year (2022) | Next Year (2023) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 3.24 | 2.71 |
| 7 Days Ago | 0 | 0 | 3.3 | 3.19 |
| 30 Days Ago | 0 | 0 | 3.32 | 3.29 |
| 60 Days Ago | 0 | 0 | 3.34 | 3.44 |
| 90 Days Ago | 0 | 0 | 3.38 | 3.51 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Dec 2022) | Next Qtr. (Mar 2023) | Current Year (2022) | Next Year (2023) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | 1 | -- |
| Up Last 30 Days | -- | -- | 2 | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | 4 | 6 |
Growth Estimates
| CURRENCY IN USD | ROVI.MC | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -- | -- | -- | 6.50% |
| Next Qtr. | -- | -- | -- | 12.00% |
| Current Year | 17.40% | -- | -- | 5.30% |
| Next Year | -16.40% | -- | -- | 13.10% |
| Next 5 Years (per annum) | 35.00% | -- | -- | 11.09% |
| Past 5 Years (per annum) | -6.14% | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
No Fair Value available for this ticker
Related Tickers
PHM.MC Pharma Mar, S.A.
28.96
+0.49%
ORY.MC Oryzon Genomics S.A.
2.0000
+0.91%
ATRY.MC Atrys Health, S.A.
2.8800
-0.35%
CAMX.ST Camurus AB (publ)
490.00
+2.81%
ABVX.PA ABIVAX Société Anonyme
14.82
+0.54%
BIOA-B.ST BioArctic AB (publ)
197.50
+1.96%
ARGX.BR argenx SE
349.30
+0.90%
YAG2.SG Atossa Therapeutics, Inc.
1.4160
+3.06%
DVHGF Devonian Health Group Inc.
0.1689
0.00%
APTCF Advanced Proteome Therapeutics Corporation
0.0002
0.00%